ReviewJournal of leukocyte biology2015
At the bench: understanding group 2 innate lymphoid cells in disease.
Review in Journal of leukocyte biology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 58 citations in OpenAlex.
- Review
- Differential roles of eosinophils in cardiovascular disease.Nature reviews. Cardiology · 2025Review
- Article
- An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.Clinical and experimental medicine · 2023Review
- Mechanisms of climate change and related air pollution on the immune system leading to allergic disease and asthma.Seminars in immunology · 2023Review
- Breaking down the complex pathophysiology of eosinophilic esophagitis.Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2023Review
- Single-cell RNA sequencing of mast cells in eosinophilic esophagitis reveals heterogeneity, local proliferation, and activation that persists in remission.The Journal of allergy and clinical immunology · 2022Article
- CD226 Deficiency Alleviates Murine Allergic Rhinitis by Suppressing Group 2 Innate Lymphoid Cell Responses.Mediators of inflammation · 2022Article
- Acupoint Catgut-Embedding Therapy Inhibits NF-BioMed research international · 2022Article
- Innate immune cell dysregulation drives inflammation and disease in aspirin-exacerbated respiratory disease.The Journal of allergy and clinical immunology · 2021Review
- Turkish Guideline for Diagnosis and Treatment of Allergic Rhinitis (ART).Turkish archives of otorhinolaryngology · 2021Article
- Innate Lymphoid Cells in Airway Inflammation.Advances in experimental medicine and biology · 2021Article
- Egg yolk augments type 2 immunity by activating innate cells.European journal of nutrition · 2020Article
- Targeted deletion of the TSLP receptor reveals cellular mechanisms that promote type 2 airway inflammation.Mucosal immunology · 2020Article
- Autophagy is critical for group 2 innate lymphoid cell metabolic homeostasis and effector function.The Journal of allergy and clinical immunology · 2020Article
- Increased expression of type 2 innate lymphoid cells in pediatric patients with allergic rhinitis.Experimental and therapeutic medicine · 2020Article
- Type 2 innate lymphoid cells participate in IL-33-stimulated Th2-associated immune response in chronic obstructive pulmonary disease.Experimental and therapeutic medicine · 2019Article
- Critical role of interleukin-23 in development of asthma promoted by cigarette smoke.Journal of molecular medicine (Berlin, Germany) · 2019Article
- Structure-Activity Relationships of Baicalein and its Analogs as Novel TSLP Inhibitors.Scientific reports · 2019Article
- Airway innate lymphoid cells in the induction and regulation of allergy.Allergology international : official journal of the Japanese Society of Allergology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
Abstract
The conventional paradigm of type 2 inflammatory responses is characterized by activation of CD4(+) Th2 cells that produce IL-4, IL-5, and IL-13, resulting in tissue eosinophil infiltration, mucus metaplasia, AHR, and IgE production. However, the recent discovery of ILC2s in mice and humans has brought forth a novel pathway in type 2 immunity that may work independent of, or in concert with, adaptive Th2 responses. ILC2s were described initially as lineage-negative lymphocytes that produce high levels of Th2 cytokines IL-5 and IL-13 in response to IL-25 and IL-33 and promote protection against helminth infections. More recent investigations have identified novel upstream regulators, as well as novel ILC2 products. ILC2s are found in mucosal surfaces, including respiratory tract and skin, and studies from experimental asthma and atopic dermatitis models support a role for ILC2s in promoting type 2 inflammatory responses. There are many unanswered questions about the role of ILC2s in chronic allergic diseases, including how ILC2s or upstream pathways can be targeted for therapy. As ILC2s are not antigen specific and may be activated after exposures to a variety of infectious agents and irritants thought to contribute to respiratory and skin diseases, future strategies to target ILC2 function in human disease may be promising. Our intent is to identify priority areas for ILC2 translational research based on basic research insights.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.